Pasithea Therapeutics Corp. Common Stock (KTTA)

Price$0.58

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-68.13%

Price vs S&P 500 (4W)-26.43%

VGM Score58.98

Market Capitalization$19.55M

All Metrics

Book Value / Share (Quarterly)$2.20

P/TBV (Annual)0.53x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.56

Price vs S&P 500 (YTD)-62.81%

Gross Margin (TTM)100.54%

Net Profit Margin (TTM)-6478.41%

EPS (TTM)$-1.98

10-Day Avg Trading Volume0.68M

EPS Excl Extra (TTM)$-1.98

EPS (Annual)$-13.01

ROI (Annual)-68.22%

Gross Margin (Annual)-14.57%

Cash / Share (Quarterly)$2.02

ROA (Last FY)-61.12%

Revenue Growth TTM (YoY)740.47%

EBITD / Share (TTM)$-1.76

Operating Margin (TTM)-7032.69%

Cash Flow / Share (Annual)$-9.99

P/B Ratio0.36x

P/B Ratio (Quarterly)0.34x

Net Income / Employee (Annual)$-3,192,300

Net Interest Coverage (TTM)-4346.00x

ROA (TTM)-53.61%

EPS Incl Extra (Annual)$-13.01

Current Ratio (Annual)6.58x

Quick Ratio (Quarterly)34.17x

3-Month Avg Trading Volume0.40M

52-Week Price Return-33.52%

Revenue / Employee (TTM)$16,047,330,000

Tangible BV / Share (Quarterly)$2.05

P/S Ratio (Annual)1294.53x

Asset Turnover (Annual)0.00x

52-Week High$2.06

EPS Excl Extra (Annual)$-13.01

26-Week Price Return-60.20%

Quick Ratio (Annual)6.31x

13-Week Price Return-25.95%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)35.40x

Enterprise Value$-30.85M

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$3,000

Pretax Margin (Annual)-14394.04%

Cash / Share (Annual)$4.97

3-Month Return Std Dev66.75%

Net Income / Employee (TTM)$-3,946,800

ROE (Last FY)-68.22%

Net Interest Coverage (Annual)-121163.20x

EPS Basic Excl Extra (Annual)$-13.01

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.98

ROI (TTM)-57.44%

P/S Ratio (TTM)26.84x

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$5.36

Price vs S&P 500 (52W)-57.89%

Year-to-Date Return-54.65%

5-Day Price Return-18.18%

EPS Normalized (Annual)$-13.01

Net Profit Margin (Annual)-14394.04%

Month-to-Date Return-18.22%

Cash Flow / Share (TTM)$-0.60

EBITD / Share (Annual)$-13.01

Operating Margin (Annual)-29850.33%

EPS Basic Excl Extra (TTM)$-1.98

P/TBV (Quarterly)0.36x

P/B Ratio (Annual)0.27x

Pretax Margin (TTM)-6478.41%

Book Value / Share (Annual)$10.60

Price vs S&P 500 (13W)-34.20%

Beta0.26x

Revenue / Share (TTM)$0.01

ROE (TTM)-57.44%

52-Week Low$0.28

gGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.12est. -0.46

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
KTTAPasithea Therapeutics Corp. Common Stock	—	A	D	$0.58
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Pasithea Therapeutics is a biotechnology company developing treatments for central nervous system disorders and genetic diseases, including neurofibromatosis type 1, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, and RASopathies. Its pipeline includes PAS-004, a MEK1/2 inhibitor; PAS-003, a monoclonal antibody; and PAS-001, a small molecule therapeutic. The company leverages expertise in neuroscience and translational medicine to address significant unmet medical needs.